
In a network meta-analysis reviewing biologics targeting IL-4/IL-13, IL-5, or IgE axes, dupilumab is the most effective type 2-targeted biologic for CRSwNP. Previous sinus surgery was not a relevant effect modifier.
authors.elsevier.com/a/1lRke7tEbbUh…

English



















